Primary Ewing’s sarcoma of the ethmoid sinus with orbital extension in a young child: A rare case and review of literature

Nirupama Kasturi, Sandip Sarkar, Tanmay Gokhale, Rajesh Nachiappa Ganesh

Key words: Ethmoid sinus, Ewing sarcoma, orbital extension

The Ewing’s sarcoma family of tumors (ESFT) is a highly malignant, small round cell neoplasm derived from primitive neuroectodermal cells with variable grades of neuronal differentiation.[1] The two primary forms are skeletal and extraskeletal ESFT. It represents the second most primary bone malignancy accounting for more than 10% of all bone tumors and 4% of head and neck tumors. The commonly affected sites are long bones of the extremities and pelvis. The extraskeletal variety primarily affects the soft tissues of the lower extremities, paravertebral tissues, chest wall, and retroperitoneum.[2]

Primary Ewing’s Sarcoma (ES) originating from the ethmoidal sinus is rare. Only a few such cases have been published to the best of our knowledge [Table 1].[3–10] We report a young boy who presented with orbital proptosis with reduced vision and was diagnosed as primary ES of the ethmoidal sinus with orbital extension; it was managed successfully with chemotherapy and radiotherapy alone.

A 13-year-old boy presented with proptosis and reduced vision of the right eye (RE) with anosmia and nasal obstruction for two months. General and systemic examination was unremarkable. Ophthalmic examination showed significant abaxial proptosis with downward (11 mm) and temporal (5 mm) displacement of the RE [Fig. 1a]. Extraocular movements were limited in supraduction and adduction. A 3 × 2 cm firm, non-compressible, tender mass was palpable in the...
superomedial region above the medial palpebral ligament. The retropulsion test was negative, and the posterior extent of the mass was not determined clinically. The best-contrast visual acuity (BCVA) was 6/60 in RE and 6/6 in the left eye (LE), and intraocular pressure was normal in both eyes. Slit-lamp examination revealed exposure keratitis inferiorly in RE. The anterior segment of LE and the dilated fundus examination of both eyes were unremarkable.

Non-contrast computed tomography (NCCT) revealed a solid mass occupying the right ethmoidal sinus extending into the superomedial extraconal space with medial and superior orbital wall erosion. A sunburst pattern of periosteal reaction was noted with loss of fat planes near the superior and medial recti. Magnetic resonance imaging (MRI) showed large circumscribed expansile lobulated T1 isointense and T2/FLAIR heterogeneously hyperintense lesion with an epicenter around the medial wall of right orbit, and ethmoid cells noted measuring about 32 × 39 × 53 mm with heterogeneous enhancement and no restricted diffusion; (c and d) MRI showing expansile heterogeneously enhancing lesion with epicenter in the medial wall of right orbit and ethmoid sinuses, with the remodeling of the floor of anterior cranial fossa with compression on the right frontal lobe; (e) MRI and (f) CT scan images showing mild proptosis with no evidence of residual mass or recurrence.

The child was treated with combined chemotherapy and radiotherapy. The chemotherapy regimen (VAC/IE) included vincristine, adriamycin, cyclophosphamide alternating with ifosfamide (2450 mg/m² on days 1–5) and etoposide (140 mg/m² on days 1–5) every two weeks for a total of 10 cycles. After completion of the chemotherapy, the child received 55.8 Gy in 31 fractions radiotherapy to the residual tumor volume using volumetric modulated arc therapy (VMAT).
Table 1: Summary of all ethmoidal Ewing’s sarcoma cases

| Author                        | Age/Sex | Location                          | Treatment                                                                 | Course                                | Follow up |
|-------------------------------|---------|-----------------------------------|---------------------------------------------------------------------------|---------------------------------------|-----------|
| Suzuki et al.[3]              | 23 y/M  | Mass involving the left nasal cavity, maxillary antrum, and ethmoid sinus | Surgical resection + Chemotherapy (VDC/IE) + RT (50.4 Gy)                  | No evidence of further disease and metastasis | 30 months |
| Li M et al.[4]                | 39 y/F  | Ethmoid sinus with intracranial and orbital extension | Chemotherapy (VDC/IE) regimen + RT (55.8 Gy)                              | Patient fully recovered without any recurrence | 32 months |
| Neguru ME et al.[5]           | 33 y/M  | Ethmoid sinus, sphenoid sinus with intracranial extension | Chemotherapy (Vincristine + Doxorubicin + Ifosfamide + G-CSF) + RT (54 Gy) | Patient fully recovered without any recurrence | 15 months |
| Aferzon et al.[6]             | 14 y/M  | Ethmoid sinus                      | Surgical excision + Chemotherapy (VDC/IE regimen) - 12 cycles + RT (5040 cGy) | Fully recovered without any recurrence or metastasis | Last follow up period not mentioned |
| Whaley et al.[7]              | 9 y/F   | Ethmoid sinus                      | Biopsy + Chemotherapy (Actinomycin D, Cyclophosphamide, Vincristine) + RT (55.8 Gy) | No evidence of disease                  | 10 years  |
| Gray et al.[8]                | 15 y/F  | Ethmoid sinus involving the skull and orbit | Chemotherapy (VDC/IE) + RT (59.4 Gy E of proton)                          | Fully recovered without any recurrence or metastasis | 12 months |
| Meccariello G et al.[9]       | 6 y/Boy | Left ethmoidal sinus with orbital extension | Neoadjuvant chemotherapy + Wide surgical excision + Brachytherapy + RT    | Disease free                           | 14 months |
| Velche-Haag et al.[10]        | Not mentioned | Ethmoid sinus | Excision + Chemotherapy + RT                                            | Full recovery                          | Not specified |

Chemo, Chemotherapy; RT, Radiotherapy; M, Male; F, Female; V, Vincristine; D, Doxorubicin; C, Cyclophosphamide; I, Ifosfamide; E, Etoposide

Sequential boost technique, and subsequently, 6 MV photons were also delivered. On completion of chemo- and radiotherapy, mild proptosis with no evidence of residual mass or recurrence was observed on repeat MRI [Fig. 2e] and CT scan [Fig. 2f]. No metabolic activity was noted on positron emission tomography–computed tomography (PET-CT). The BCVA improved to 6/6 with complete resolution of proptosis [Fig. 1b]. The child has been on follow-up after completion of therapy for the last 32 months and has been disease-free to date.

Discussion

ESFT includes skeletal or soft tissue ES, peripheral primitive neuroectodermal tumors of bone (pPNET), and Askin’s (thoracopulmonary) tumors.[1,3] Primary ES commonly occurs in early childhood or adolescence with male gender predominance. Histopathologically, ES comprises of uniform small round cells with round nuclei containing fine chromatin, scanty clear or eosinophilic cytoplasm, and PAS-positive intracytoplasmic glycogen granules.[4] Other small round cell tumors such as ESFT, neuroblastoma, rhabdomyosarcoma, lymphoma, osteogenic sarcoma, and mesenchymal chondrosarcoma share similar characteristics. Hence, clinical, radiological, histopathological, and cytogenetic analyses are needed for diagnosis.

ES is characterized by the fusion of FLI1, ERG genes with the EWS gene, and translocation of the EWS gene at 22q12 position. The EWS gene is fused with the FLI1 gene located on 11q24, causing a translocation at t(22;11), finally leading to an EWS–FLI1 fusion gene found in more than 85% of the cases of ES.[1] Sinonasal ES can affect the frontal, ethmoidal, maxillary sinuses, or the nasal cavity presenting as an increasing mass, nasal blockage, rhinorrhea, epistaxis, and proptosis due to orbital extension.[4,9] The maxillary followed by the ethmoid are most commonly affected sinus. Ethmoidal sinus ES can extend towards the maxillary sinus, sphenoid sinus, nasal cavity, orbits, and intracranial. Ethmoid sinus has minimal space and thin, bony lamina papyracea causing direct tumor extension into the orbits.[14] About 18% of ES patients present with metastasis as an initial presentation, with lungs and bones being the commonest site.[15] The prognosis varies with the patient’s age, location, the presence of distant metastasis, and associated comorbidities. The recent advances in the treatment protocol of ES have improved the survival rate in patients without metastatic diseases.[3] A multidisciplinary treatment protocol with chemoreduction followed by debulking surgery, adjuvant chemotherapy, and radiotherapy is required for a favorable outcome. The recommended chemotherapy regimen is alternating cycles of vincristine-doxorubicin, cyclophosphamide, and ifosfamide, etoposide.[12] In our case, the patient responded well to chemotherapy and radiotherapy. Surgical resection of the tumor was not needed as it showed complete resolution on a repeat CT scan following complete therapy. Similar to ours, few cases of ethmoid sinus ES were managed with chemotherapy and radiotherapy alone, with favorable outcomes reported.[16] We have been following this child for 32 months and have been disease-free since then. Our case shows that successful outcomes can be achieved in these cases with timely diagnosis and treatment with chemotherapy and radiotherapy only.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other
clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Kasturi N, Sarkar S, Gokhale T, Kaliaperumal S, Ch Tot P, Ramamoorthy JG, et al. Congenital primary primitive neuroectodermal tumor of the orbit in a newborn. Eur J Ophthalmol 2021:1120672121991047. doi: 10.1177/1120672121991047.

2. Martin E, Radomski S, Harley EH. Pediatric Ewing sarcoma of the head and neck: A retrospective survival analysis. Int J Pediatr Otorhinolaryngol 2019;117:138-42.

3. Suzuki T, Yasumatsu R, Nakashima T, Arita S, Yamamoto H, Nakagawa T. Primary Ewing’s sarcoma of the sinonasal tract: A case report. Case Rep Oncol 2017;10:91-7.

4. Li M, Hoschar AP, Budd GT, Chao ST, Scharpf J. Primary Ewing’s sarcoma of the ethmoid sinus with intracranial and orbital extension: Case report and literature review. Am J Otolaryngol 2013;34:563-8.

5. Negru ME, Spongini AP, Rondonotti D, Platini F, Giavarra M, Forti L, et al. Primary Ewing’s sarcoma of the sinonasal tract, eroding the ethmoid and sphenoid sinus with intracranial extension: A rare case report. Mol Clin Oncol 2015;3:807-10.

6. Aférzon M, Wood WE, Powell JR. Ewing’s sarcoma of the ethmoid sinus. Otolaryngol Head Neck Surg 2003;128:897-901.

7. Whaley JT, Indelicato DJ, Morris CG, Hinerman RW, Amdur RJ, Mendenhall WM, et al. Ewing Tumors of the head and neck. Am J Clin Oncol 2010;33:321-6.

8. Gray ST, Chen Y-L, Lin DT. Efficacy of proton beam therapy in the treatment of ewing’s sarcoma of the paranasal sinuses and anterior skull base. Skull Base 2009;19:409-16.

9. Meccariello G, Merks JHM, Pieters BR, van Furth WR, Saeed P, Schoot RA, et al. Endoscopic management of Ewing’s sarcoma of ethmoid sinus within the AMORE framework: A new paradigm. Int J Pediatr Otorhinolaryngol 2013;77:139-43.

10. Velche-Haag B, Dehesdin D, Proust F, Marie JP, Andrieu-Guitrancourt J, Laquerriere A. Ewing’s sarcoma of the head and neck: a case report. InAnnales D’oto-laryngologie et de Chirurgie Cervico Faciale: Bulletin de la Societe D’oto-laryngologie des Hopitaux de Paris 2002 Dec 1 (Vol. 119, No. 6, pp. 363-368).